MedTrace Logo

Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction

NCT06211166 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2024-01-18

No results posted yet for this study

Summary

A research investigation into the efficacy of digital Polymerase Chain Reaction (dPCR) for monitoring measurable residual disease (MRD) during allogeneic hematopoietic stem cell transplantation, with a focus on predicting relapse in patients diagnosed with leukemia, myelodysplastic syndromes (MDS), and related hematological conditions.

Conditions

Interventions

DIAGNOSTIC_TEST

Digital PCR

digital Polymerase Chain Reaction (dPCR)

DIAGNOSTIC_TEST

Quantitative PCR

Real-time Polymerase Chain Reaction (real-time PCR)

DIAGNOSTIC_TEST

MFC

Multicolor Flow Cytometry

Sponsors & Collaborators

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Xiao-jun Huang, M.D · Peking University People's Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-08
Primary Completion
2025-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06211166 on ClinicalTrials.gov